Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/6/2026

1. MU
2. SPY
3. APTX:CN
4. IQMX
5. EROC
6. MSFT
7. MSTR
8. SEER
9. NVDA
10. TSLA

Go back to Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients
(NASDAQ: ABVX) Delayed: 146.09 +1.44 (1.00%)
Previous Close $144.65    52 Week High $ 
Open $146.15    52 Week Low $ 
Day High $147.98    P/E N/A 
Day Low $143.03    EPS $ 
Volume 1,084,829       

(NASDAQ: ABVX) Delayed: 146.09 +1.44 (1.00%)
Previous Close $144.65    52 Week High $ 
Open $146.15    52 Week Low $ 
Day High $147.98    P/E N/A 
Day Low $143.03    EPS $ 
Volume 1,084,829